Corneal collagen cross-linking using riboflavin and ultraviolet-A irradiation: a review of clinical and experimental studies
Corneal collagen cross-linking using riboflavin and ultraviolet-A irradiation: a review of clinical and experimental studies
复制标题
DOI：
10.1007/s10792-011-9460-x
复制
发表时间：
2011-08-01
影响因子：
1.6
通讯作者：
Kozobolis, Vassilios
中科院分区：
文献类型：
--
作者：
Gkika, Maria;Labiris, Georgios;Kozobolis, Vassilios
使用核黄素和紫外线A照射的角膜胶原交联(CXL)是一种常见的组织稳定方法，主要用于治疗圆锥角膜。CXL治疗圆锥角膜的有希望的结果表明，它也可能对其他角膜疾病有效。这种新的治疗方法有望减缓这些疾病的进展，其初步结果表明，它是安全和合理的疗效。这篇综述的目的是对这种治疗方法进行批判性的评估，探索其益处，突出其在有效性和长期安全性方面的局限性，并最终确定这一主题的未来研究领域，这些领域有可能改变我们治疗患者的方式。此外，在这篇不偏不倚的综述中，我们试图汇集近年来进行的实验室和临床试验的所有科学信息，并回顾关于CXL治疗适应症的最新出版物。
Corneal collagen cross-linking (CXL) using riboflavin and ultraviolet-A irradiation is a common method of tissue stabilization and has been developed primarily to address the need of treating keratoconus. CXL's promising results on keratoconus indicated that it might be effective in other corneal diseases as well. This new treatment promises a slowing effect on the progression of these diseases and its initial results show that it is safe and reasonably curative. The purpose of this review is to critically evaluate this treatment, to explore its benefits, to highlight its limitations in terms of efficacy and long-term safety and finally to identify areas for future research in this topic with a significant potential to change the way we treat our patients. In addition, in this unbiased review we try to bring together all the scientific information from both laboratory and clinical trials that have been conducted during recent years and to review the most recent publications regarding the therapeutic indications of CXL.